United Kingdom

People: ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

17 Jul 2019
Change (% chg)

$-0.10 (-2.67%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sullivan-Bolyai, John 

Dr. John Z. Sullivan-Bolyai M.D., is Chief Medical Officer of the Company. From August 2014 until January 2015, Dr. Sullivan- Bolyai was the Executive Director of Infectious Disease clinical research at Merck & Co. Inc. where he oversaw multiple HCV protocols in all three phases of clinical development. From June 2007 until August 2014, he was the Vice-President of Clinical Research at Idenix Pharmaceuticals Inc. where he managed all medical aspects of the HIV and HCV programs. Additionally, he was responsible for the transition of Idenix’s clinical team to Merck, which acquired Idenix. Prior to joining Idenix, Dr. Sullivan-Bolyai worked at Anadys Pharmaceuticals on hepatitis C and at Valeant Pharmaceuticals International on Valeant’s nucleotide prodrug for the treatment of chronic hepatitis B infection. Previously, he held various medical and operations positions at Biomeasure and Serono Laboratories in Massachusetts, working on coagulation, immunomodulatory, endocrine, and gastrointestinal compounds. He began his career with Hoffmann-La Roche where he worked on a variety of compounds for the treatment of bacterial infections, HCV and HIV. Dr. Sullivan-Bolyai received an MD, MPH from the University of Washington in Seattle. He completed his infectious diseases fellowship training at the Children’s Orthopedic Hospital and Medical Center, Seattle, WA, followed by academic positions at UCLA and the University of Illinois.

Basic Compensation

Total Annual Compensation, USD 332,800
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 102,904
Fiscal Year Total, USD 435,704

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --